Infantile Spasms Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, China - Size and Forecast 2024-2028

Published: Dec 2023

Pages: 154

SKU: IRTNTR77025

Snapshot

Infantile Spasms Therapeutics Market Forecast 2024-2028

The global infantile spasms therapeutics market size is estimated to grow by USD 89.61 million at a CAGR (Compound Annual Growth Rate) of 5.41% between 2023 and 2028.

Ongoing research in neurology and epilepsy is driving the development of new therapeutic possibilities in the market for infantile spasms therapeutics. Collaboration between pharmaceutical companies and academic institutes fosters a conducive climate for breakthroughs, fostering multidisciplinary investigation. As a result, the market benefits from a steady infusion of cutting-edge treatment choices, which improves the overall efficacy and specificity of infantile spasm therapeutics. This dynamic landscape puts continuing neurology and epilepsy research as a critical driver for revolutionary advances in the treatment.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation by Route Of Administration, Drug Class and Geography Analysis

Route Of Administration Analysis

The market share growth by the parenteral segment will be significant during the forecast period. In the market, the parental route of administration is developing as a major approach, providing direct and efficient drug delivery. Parenteral formulations such as intravenous and intramuscular injections, ensure rapid and exact medication distribution, which is essential in the treatment.

Get a glance at the market contribution of various segments Download PDF Sample

The parenteral segment was the largest and was valued at USD 225.03 million in 2018. Parenterally provided drugs include Adrenocorticotropic hormone (ACTH) and vigabatrin, which are routinely used to treat infantile spasms. The parenteral approach improves bioavailability, allowing for faster therapeutic effects. This trend corresponds to the critical need for rapid intervention in the treatment of infantile spasms, emphasizing the importance of parenteral administration in delivering therapeutics directly into the bloodstream for optimal efficacy, making it a pivotal and increasingly preferred route of administration in the evolving landscape of Infantile Spasms Therapeutics. Conclusively, the increasing prevalence of parental routes for the administration is expected to drive the growth of the market during the forecast period.

Drug Class Analysis

Anticonvulsants are a leading drug class in the market, playing a critical role in controlling and reducing spasms caused by this neurological condition. ACTH, vigabatrin, and oral corticosteroids are examples of drugs in this class that have shown success in reducing seizures. As anticonvulsants remain an essential drug class in Infantile Spasms Therapeutics, developments and innovations within this drug class are projected to fuel continued expansion of the anticonvulsants segment during the forecast period, providing superior management options for people suffering from this ailment. This, in turn, will drive the growth of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The market in North America has witnessed a significant growth potential in recent years. The high prevalence of infantile spasms, a well-established healthcare infrastructure, and increased awareness about early diagnosis and intervention are driving this expansion. The region's powerful R&D ecosystem encourages therapeutic approach innovation. Leading pharmaceutical businesses such as Mallinckrodt and H Lundbeck actively contribute to regional market growth by developing new drugs. Collaborations among research institutions, healthcare providers, and advocacy groups improve the market landscape even more.

However, challenges include the need for improved awareness as well as potential regulatory stumbling blocks. The North American market is positioned for sustained expansion, offering advanced treatment options for affected individuals, thanks to a patient-centric approach, ongoing research endeavors, and an emphasis on precision medicine. Owing to such factors. The regional market is expected to grow at a significant rate during the forecast period.

Buy the Full Report Now

Key Infantile Spasms Therapeutics Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market growth analysis report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Amneal Pharmaceuticals Inc. - The company offers infantile spasms therapeutics such as vigabatrin tablet used as monotherapy to treat infantile spasms in infants 1 month to 2 years.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the trends, and challenges.

Significant Trends

Growing interest in gene therapy is one of the major market trends. With increased interest in gene therapy as a viable treatment technique, the market is experiencing a major development. By directly treating the genetic causes underlying infantile spasms, gene therapy provides focused and personalized therapeutic alternatives. Researchers are actively investigating strategies for modifying or replacing faulty genes related to the disorder. For example, ongoing research is focusing on changing certain genes to modulate neural activity and reduce spasms. This movement represents a paradigm shift towards precision medicine, in which therapies are personalized to patients' unique genetic composition.

Further, the pursuit of gene therapy improvements holds the promise of more effective and precisely customized solutions for infantile spasms, showing a revolutionary potential in therapeutic interventions and offering better outcomes for those affected by this neurological illness. Hence, the growing interest in gene therapy is expected to drive the growth of the market during the forecast period.

Major Challenges

Lack of awareness about infantile spasms among healthcare professionals and caregivers is an emerging challenge. The market faces significant challenges due to a lack of understanding regarding infantile spasms among healthcare professionals and caregivers. This lack of awareness can lead to delayed diagnosis and treatment initiation, both of which have a significant impact on patient outcomes. Healthcare providers may misread symptoms, resulting in misdiagnosis or delayed diagnosis, whereas caregivers may fail to recognize the importance of obtaining quick medical help.

However, to address this issue, comprehensive educational initiatives aimed at healthcare professionals, caregivers, and the general public must be implemented to raise awareness, promote early detection, and facilitate timely access to Infantile Spasms Therapeutics, ultimately improving patient care and overall treatment effectiveness. Owing to all such factors, the market is expected to witness a hindrance in growth during the forecast period.

Buy Now Full Report

Key Customer Landscape

The market growth analysis report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Customer Landscape

Market Analyst Overview

The infantile spasms therapeutics market addresses conditions like West syndrome, triggered by factors such as brain tumors, birth injuries, or genetic abnormalities. With ongoing product innovation and government initiatives, research and development activities propel the market forward. Pipeline drugs offer hope, albeit with considerations like treatment costs and regulations. Dosage precision and suitable distribution channels ensure efficacy, with end-users benefiting from improved healthcare expenditure allocation. Regions like Mexico witness notable developments in this sector, reflecting a global commitment to combatting infantile spasms and providing comprehensive care for affected children, highlighting the importance of concerted efforts in advancing therapeutic solutions.

Segment Overview

The market research and growth report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.

Route Of Administration Outlook
- Parenteral
- Oral

Drug Class Outlook
- Anticonvulsants
- Corticosteroids
- Others

Region Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of World (ROW)
  - Brazil
  - Argentina
  - Australia

Infantile Spasms Therapeutics Market Scope
Market Report Coverage	Details
Page number	154
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 5.41%
Market Growth 2024-2028	USD 89.61 million
Market structure	Fragmented
YoY growth 2023-2024(%)	4.52
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 44%
Key countries	US, Germany, UK, France, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Amneal Pharmaceuticals Inc., Cipla Ltd., Endo International Plc, H Lundbeck AS, Hetero Labs Ltd., Intas Pharmaceuticals Ltd., Jazz Pharmaceuticals Plc, Mallinckrodt Plc, Marinus Pharmaceuticals Inc., MSN Laboratories, Ovid Therapeutics Inc., Sanofi SA, SGPharma Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Anavex Life Sciences Corp., Genix Pharma Pvt. Ltd., Jolly Healthcare, and ORPHELIA Pharma
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our market forecasting report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the market between 2024 and 2028
Precise estimation of the market size and its contribution of the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global infantile spasms therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global infantile spasms therapeutics market 2018 - 2022 ($ million)

4.2 Route of Administration Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Route of Administration Segment 2018 - 2022 ($ million)

4.3 Drug Class Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Drug Class Segment 2018 - 2022 ($ million)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Route of Administration

6.1 Market segments
- Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)

6.2 Comparison by Route of Administration
- Exhibit 32: Chart on Comparison by Route of Administration
- Exhibit 33: Data Table on Comparison by Route of Administration

6.3 Parenteral - Market size and forecast 2023-2028
- Exhibit 34: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)

6.4 Oral - Market size and forecast 2023-2028
- Exhibit 38: Chart on Oral - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)

6.5 Market opportunity by Route of Administration
- Exhibit 42: Market opportunity by Route of Administration ($ million)
- Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

7.1 Market segments
- Exhibit 44: Chart on Drug Class - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Drug Class - Market share 2023-2028 (%)

7.2 Comparison by Drug Class
- Exhibit 46: Chart on Comparison by Drug Class
- Exhibit 47: Data Table on Comparison by Drug Class

7.3 Anticonvulsants - Market size and forecast 2023-2028
- Exhibit 48: Chart on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
- Exhibit 49: Data Table on Anticonvulsants - Market size and forecast 2023-2028 ($ million)
- Exhibit 50: Chart on Anticonvulsants - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Anticonvulsants - Year-over-year growth 2023-2028 (%)

7.4 Corticosteroids - Market size and forecast 2023-2028
- Exhibit 52: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)

7.5 Others - Market size and forecast 2023-2028
- Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Drug Class
- Exhibit 60: Market opportunity by Drug Class ($ million)
- Exhibit 61: Data Table on Market opportunity by Drug Class ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Germany - Market size and forecast 2023-2028
- Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.9 UK - Market size and forecast 2023-2028
- Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.10 France - Market size and forecast 2023-2028
- Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)

9.11 China - Market size and forecast 2023-2028
- Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 Amneal Pharmaceuticals Inc.
- Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus

12.4 Cipla Ltd.
- Exhibit 116: Cipla Ltd. - Overview
- Exhibit 117: Cipla Ltd. - Business segments
- Exhibit 118: Cipla Ltd. - Key news
- Exhibit 119: Cipla Ltd. - Key offerings
- Exhibit 120: Cipla Ltd. - Segment focus

12.5 Endo International Plc
- Exhibit 121: Endo International Plc - Overview
- Exhibit 122: Endo International Plc - Business segments
- Exhibit 123: Endo International Plc - Key news
- Exhibit 124: Endo International Plc - Key offerings
- Exhibit 125: Endo International Plc - Segment focus

12.6 H Lundbeck AS
- Exhibit 126: H Lundbeck AS - Overview
- Exhibit 127: H Lundbeck AS - Product / Service
- Exhibit 128: H Lundbeck AS - Key offerings

12.7 Hetero Labs Ltd.
- Exhibit 129: Hetero Labs Ltd. - Overview
- Exhibit 130: Hetero Labs Ltd. - Product / Service
- Exhibit 131: Hetero Labs Ltd. - Key offerings

12.8 Intas Pharmaceuticals Ltd.
- Exhibit 132: Intas Pharmaceuticals Ltd. - Overview
- Exhibit 133: Intas Pharmaceuticals Ltd. - Product / Service
- Exhibit 134: Intas Pharmaceuticals Ltd. - Key offerings

12.9 Jazz Pharmaceuticals Plc
- Exhibit 135: Jazz Pharmaceuticals Plc - Overview
- Exhibit 136: Jazz Pharmaceuticals Plc - Product / Service
- Exhibit 137: Jazz Pharmaceuticals Plc - Key news
- Exhibit 138: Jazz Pharmaceuticals Plc - Key offerings

12.10 Mallinckrodt Plc
- Exhibit 139: Mallinckrodt Plc - Overview
- Exhibit 140: Mallinckrodt Plc - Business segments
- Exhibit 141: Mallinckrodt Plc - Key offerings
- Exhibit 142: Mallinckrodt Plc - Segment focus

12.11 Marinus Pharmaceuticals Inc.
- Exhibit 143: Marinus Pharmaceuticals Inc. - Overview
- Exhibit 144: Marinus Pharmaceuticals Inc. - Product / Service
- Exhibit 145: Marinus Pharmaceuticals Inc. - Key offerings

12.12 MSN Laboratories
- Exhibit 146: MSN Laboratories - Overview
- Exhibit 147: MSN Laboratories - Product / Service
- Exhibit 148: MSN Laboratories - Key offerings

12.13 Ovid Therapeutics Inc.
- Exhibit 149: Ovid Therapeutics Inc. - Overview
- Exhibit 150: Ovid Therapeutics Inc. - Product / Service
- Exhibit 151: Ovid Therapeutics Inc. - Key offerings

12.14 Sanofi SA
- Exhibit 152: Sanofi SA - Overview
- Exhibit 153: Sanofi SA - Business segments
- Exhibit 154: Sanofi SA - Key news
- Exhibit 155: Sanofi SA - Key offerings
- Exhibit 156: Sanofi SA - Segment focus

12.15 SGPharma Pvt. Ltd.
- Exhibit 157: SGPharma Pvt. Ltd. - Overview
- Exhibit 158: SGPharma Pvt. Ltd. - Product / Service
- Exhibit 159: SGPharma Pvt. Ltd. - Key offerings

12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus

12.17 Zydus Lifesciences Ltd.
- Exhibit 165: Zydus Lifesciences Ltd. - Overview
- Exhibit 166: Zydus Lifesciences Ltd. - Business segments
- Exhibit 167: Zydus Lifesciences Ltd. - Key offerings
- Exhibit 168: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 169: Inclusions checklist
- Exhibit 170: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 171: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 172: Research methodology
- Exhibit 173: Validation techniques employed for market sizing
- Exhibit 174: Information sources

13.5 List of abbreviations
- Exhibit 175: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

infantile spasms therapeutics market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis